Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts. Show more

Location: 1210-1220 Washington St., Newton, MA, 02465, United States | Website: https://acumenpharm.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

86.01M

52 Wk Range

$0.85 - $3.36

Previous Close

$1.42

Open

$1.41

Volume

479,382

Day Range

$1.19 - $1.44

Enterprise Value

-33.35M

Cash

149.1M

Avg Qtr Burn

-25.62M

Insider Ownership

11.46%

Institutional Own.

71.64%

Qtr Updated

03/31/25